Table 1 Characteristics of the study population organized according to the groups and according to demographic/medical record, anticoagulation treatment, and outcomes (gestation related and coagulation related)

Baseline

Age (mean ± SD)

33.5 ± 4.6

37.2 ± 5.1

32.5 ± 4.4

 < .0001

BMI (mean, SD)

24.4 ± 3.9

24.7 ± 3.8

24.4 ± 4.3

0.4281

No. of foetuses at the observed gestation (N, %)

 < .0001

1

434, 97.5%

102, 77.3%

158, 95.8%

 ≥ 2

11, 2.5%

30, 22.7%

7, 4.2%

High risk Thrombophilia (positive cases)

10.10%

9.90%

10.30%

0.9916

Treatment

Mean Duration of LMWH (months)

8.7 ± 1.3

8.7 ± 1.7

8.3 ± 1.6

 < .0001

Fixed Prophylactic Dose

58.90%

50%

52.10%

0.1100

Weight Adjusted prophylactic dose

32.40%

38.60%

37.00%

0.3092

Therapeutic dose of LMWH

8.80%

11.40%

10.90%

0.5663

Concomitant Use of ASA

18.20%

30.30%

12.10%

0.0003

Outcomes

Caesarian

79.70%

91.70%

65.50%

 < .0001

Live Birth

99.10%

97.00%

99.40%

0.1039

Gestational Vascular Complications (Total) (N, %)

37 (8.3%)

23 (17.4%)

16 (9.7%)

0.0097

IUGR

13 (2.9%)

8 (6.1%)

5 (3.0%)

0.2114

Preterm Labor

19 (4.3%)

12 (9.1%)

10 (6.1%)

0.0978

Fetal Death

1 (0.2%)

1 (0.8%)

0.5981

Early pregnancy loss/abortion

3 (0.7%)

2 (1.5%)

0.5427

Pre-eclampsia/eclampsia

1 (0.2%)

1 (0.6%)

0.6301

VTE [VTE postpartum]^a

3 (0.7%) [3 (0.7%)] (5 women)

0 [1 (0.8%)] (1 woman)

1 (0.6%) [5 (3.0%)] (6 women)

0.0632

Bleeding

6 (1.3%)

5 (3.8%)

1 (0.6%)

0.0728